Atlas Trials

HER2-low or HER2-ultralow

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch HER2-low or HER2-ultralow

RecordFirmDate
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer (NCT07701941)Daiichi Sankyo2026-08-03

Track HER2-low or HER2-ultralow automatically

Every clearance here is in the API, with alerts when new ones post.